Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will hold an Investor Relations (IR) session at Conrad Seoul (Yeouido) for domestic institutional investors to provide updates on its bio platform technologies and pipeline plans.
📊 [Key Disclosure Details & Major Figures Summary]
- Event Name: IR and Q&A Session for Institutional Investors
- Date & Time: April 09, 2026, 11:00 – 12:30 (Local Time)
- Location: Conrad Yeouido
- Target Audience: Domestic institutional investors
- Purpose: To enhance investor understanding regarding corporate presentation and key business status
- Method: IR presentation and Q&A session for institutional investors
- Key Details: Updates on bio platform technologies, pipeline status, and future plans
- Confirmation Date: April 07, 2026
- Contact Department: IR Team (Tel: +82-42-384-8777)
- IR Material Publication: Scheduled for publication on April 09, 2026, on the KRX KIND system website (http://kind.krx.co.kr)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Platform Technologies and Pipeline Updates via Published IR Materials
The company plans to publish its IR presentation materials on the KRX KIND system on April 09, 2026, for this event. Reviewing the official presentation materials provided to domestic institutional investors is essential because it allows investors to accurately understand the development progress of the company’s bio platform technologies and pipeline strategic directions. Detailed contents can be cross-checked in the official IR presentation materials published on the KRX KIND system website.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
